iCAD, Inc. (NASDAQ:ICAD) Short Interest Update

iCAD, Inc. (NASDAQ:ICAD) was the recipient of a large decrease in short interest in the month of November. As of November 15th, there was short interest totalling 233,000 shares, a decrease of 6.5% from the October 31st total of 249,100 shares. Based on an average trading volume of 203,500 shares, the days-to-cover ratio is presently 1.1 days. Approximately 0.9% of the shares of the stock are sold short.

Hedge Funds Weigh In On iCAD

Several hedge funds have recently made changes to their positions in the company. Virtu Financial LLC raised its position in shares of iCAD by 55.6% during the 1st quarter. Virtu Financial LLC now owns 21,286 shares of the technology company’s stock valued at $34,000 after buying an additional 7,604 shares during the period. Perritt Capital Management Inc boosted its stake in shares of iCAD by 14.2% during the 2nd quarter. Perritt Capital Management Inc now owns 159,900 shares of the technology company’s stock worth $208,000 after purchasing an additional 19,917 shares during the last quarter. Finally, Essex LLC purchased a new stake in iCAD during the third quarter valued at about $216,000. 24.61% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, StockNews.com raised shares of iCAD from a “sell” rating to a “hold” rating in a research report on Thursday, November 21st.

iCAD Trading Up 1.7 %

Shares of NASDAQ:ICAD opened at $1.76 on Tuesday. iCAD has a twelve month low of $1.18 and a twelve month high of $2.65. The firm’s 50 day moving average price is $1.73 and its 200-day moving average price is $1.55.

iCAD Company Profile

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.